No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
www.hybio.com.cnNo one on the platform currently holds 300199.SZ.
No tracked institution reports a position in 300199.SZ as of their last filing.
No one on the platform has traded 300199.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 1.7% | — | — | — | ||
| Rev. Growth % | 63.7% | 6.0% | ||||
| Profit Margin % | 3.8% | -38.6% | -38.8% | |||
| Free Cash Flow Margin % | -0.0% | -8.4% | -15.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.5B | +38.0% | $0.47 | $0.47–$0.47 | — | 1 |
| 2027 | $1.9B | +27.9% | $0.65 | $0.65–$0.65 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300199.SZHybio Pharmaceutical Co., Ltd. | $23.59 | +0.34% | $20.8B | — |
| 000739.SZApeloa Pharmaceutical Co.,Ltd | $22.37 | -1.37% | $25.9B | — |
| 002317.SZGuangdong Zhongsheng Pharmaceutical Co., Ltd. | $24.80 | -0.36% | $21.1B | — |
| 002399.SZShenzhen Hepalink Pharmaceutical Group Co., Ltd. | $9.38 | -2.39% | $11.7B | — |
| 002755.SZBeijing Aosaikang Pharmaceutical Co., Ltd. | $11.26 | -1.23% | $10.5B | — |
| 300142.SZWalvax Biotechnology Co., Ltd. | $13.01 | -2.84% | $20.8B | — |
| 300436.SZFujian Cosunter Pharmaceutical Co., Ltd. | $84.88 | -2.23% | $13.5B | — |
Source: Financial Modeling Prep · peers by sector/industry